{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:16:37Z","timestamp":1694063797964},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.cld.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T22:00:55Z","timestamp":1501970455000},"page":"645-657","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatitis C Genotype 3 Infection"],"prefix":"10.1016","volume":"21","author":[{"given":"Haripriya","family":"Maddur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2017.06.009_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","article-title":"Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients","volume":"40","author":"Planas","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12072-015-9621-5","article-title":"Management of post transplant hepatitis C in the direct antiviral agents era","volume":"9","author":"Coilly","year":"2015","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2017.06.009_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2017.06.009_bib5","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.cgh.2015.07.015","article-title":"Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients?","volume":"13","author":"Muir","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2017.06.009_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/jvh.12168","article-title":"Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3","volume":"20","author":"Tapper","year":"2013","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.cld.2017.06.009_bib7","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","article-title":"The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry","volume":"174","author":"McCombs","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2017.06.009_bib9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2017.06.009_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.cld.2017.06.009_bib11","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"21","key":"10.1016\/j.cld.2017.06.009_bib12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.cld.2017.06.009_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1665-2681(19)31735-1","article-title":"Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications","volume":"9","author":"Arrese","year":"2010","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2017.06.009_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.2002.009936","article-title":"Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis","volume":"53","author":"Castera","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2017.06.009_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jhep.2003.50267","article-title":"Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C","volume":"38","author":"Poynard","year":"2003","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2017.06.009_bib16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/gut.52.11.1638","article-title":"Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C","volume":"52","author":"Asselah","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2017.06.009_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gut.2003.018770","article-title":"Steatosis affects chronic hepatitis C progression in a genotype specific way","volume":"53","author":"Rubbia-Brandt","year":"2004","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2017.06.009_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2004.12.034","article-title":"An in\u00a0vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation","volume":"42","author":"Abid","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12035","article-title":"Hepatitis C virus diversity and hepatic steatosis","volume":"20","author":"Roingeard","year":"2013","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.cld.2017.06.009_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2017.06.009_bib21","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2017.06.009_bib22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/jhep.2002.36370","article-title":"Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response","volume":"36","author":"Kumar","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2017.06.009_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3","volume":"33","author":"Rubbia-Brandt","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2017.06.009_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2017.06.009_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diseases AAftSoL. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"13","key":"10.1016\/j.cld.2017.06.009_bib27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2017.06.009_bib28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9286","key":"10.1016\/j.cld.2017.06.009_bib29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2017.06.009_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"25","key":"10.1016\/j.cld.2017.06.009_bib31","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24\u00a0weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cld.2017.06.009_bib32","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cld.2017.06.009_bib33","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.06.009_bib34","doi-asserted-by":"crossref","unstructured":"Foster GR, Pianko S, Cooper C, et\u00a0al. Sofosbuvir plus Peg-IFN\/RBV for 12\u00a0weeks versus sofosbuvir\/RBV for 16 or 24\u00a0weeks in genotype 3 HCV-infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON Study. Abstract 2015; Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, April 22\u201326, 2015.","DOI":"10.1016\/S0168-8278(15)30151-3"},{"issue":"16","key":"10.1016\/j.cld.2017.06.009_bib35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMc1401726","article-title":"Daclatasvir plus sofosbuvir for HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2017.06.009_bib36","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.06.009_bib37","doi-asserted-by":"crossref","unstructured":"Welzel TM, Herzer K, Ferenci P, et\u00a0al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. Vienna, Austria, EASL April 22\u201326, Abstract 2015.","DOI":"10.1016\/S0168-8278(15)30975-2"},{"key":"10.1016\/j.cld.2017.06.009_bib38","doi-asserted-by":"crossref","unstructured":"Gane EJ, Hyland RH, An D. Sofosbuvir\/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Abstract 2014; Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver. London, England, April 9\u201313, 2014.","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"10.1016\/j.cld.2017.06.009_bib39","unstructured":"Gane EJ, Hyland RH, An, D, et\u00a0al. Once-daily sofosbuvir with GS-5816 for 8\u00a0weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON-2 Study. Abstract AASLD 2014 Boston, November 8\u201311, 2014."},{"issue":"11","key":"10.1016\/j.cld.2017.06.009_bib40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann Intern Med"},{"issue":"27","key":"10.1016\/j.cld.2017.06.009_bib41","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.cld.2017.06.009_bib42","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2017.06.009_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","article-title":"Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10003","key":"10.1016\/j.cld.2017.06.009_bib44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2017.06.009_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.06.009_bib46","unstructured":"Gane E. EXPEDITION-IV: Safety and efficacy of GLE\/PIB in adults with renal impairment and chronic hepatitis C virus genotype 1-6 infection. 67th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, USA, November 11\u201315, abstract LB-11, 2016."},{"key":"10.1016\/j.cld.2017.06.009_bib47","doi-asserted-by":"crossref","unstructured":"Lawitz E. Safety and efficacy of the fixed-dose combination regimen of MK-3682\/grazoprevir\/MK-8408 (ruzasvir) with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2 or 3 infection (Part B of C-CREST-1 & -2) Presented at the American Association for the Study of Liver Disease. Boston, MA, November 11\u201315, 2016.","DOI":"10.1016\/S0168-8278(17)30952-2"},{"key":"10.1016\/j.cld.2017.06.009_bib48","doi-asserted-by":"crossref","unstructured":"Serfaty EA. High sustained virologic response rates in patients with chronic HCV GT1, 2 or 3 infection following 16\u00a0weeks of MK-3682, grazoprevir\/MK-8408 (ruzasvir) plus ribavirin after failure of 8\u00a0weeks of therapy (Part C of C-CREST-1 &2) Presented at the American Association for the Study of Liver Disease. Boston, MA, November 7\u201311, 2016.","DOI":"10.1016\/S0168-8278(17)30931-5"},{"key":"10.1016\/j.cld.2017.06.009_bib49","unstructured":"Bourli\u00e8re MEA. Sofosbuvir\/velpatasvir\/voxilaprevir for 12\u00a0weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: the phase 3 POLARIS-1 Study, presented at the American Association for the Study of Liver Diseases Meeting. Boston, MA, November 7\u201311, 2016."},{"key":"10.1016\/j.cld.2017.06.009_bib50","unstructured":"Zeuzem S. A randomized, controlled, phase 3 trial of sofosbuvir\/velpatasvir\/voxilaprevir or sofosbuvir\/velpatasvir for 12\u00a0weeks in direct-acting antiviral-experienced patients with genotype 1-6 HCV infection: the POLARIS-4 Study Presented at the American Association of the Study of Liver Disease. Boston, MA, November, 2016."},{"key":"10.1016\/j.cld.2017.06.009_bib51","unstructured":"Recommendations for testing, managing, and treating hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. 2014. Available at: http:\/\/www.hcvguidelines.org\/. Accessed October 6, 2015."}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T20:52:34Z","timestamp":1659300754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326117300570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1089326117300570"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2017.06.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Genotype 3 Infection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}